Multi-marker testing for cancer: what can we learn from modern prenatal testing for Trisomy-21 by Schneider, Erasmus & Mizejewski, Gerald
R E V I E W
Cancer Informatics 2006:2 44-47 44
Correspondence: Erasmus Schneider, Ph.D., Phone: 518-474-2088, Fax: 518-474-1850, schneid@wadsworth.org
Multi-marker testing for cancer: what can we learn 
from modern prenatal testing forTrisomy-21
Erasmus Schneider and Gerald Mizejewski
Wadsworth Center, New York State Department of Health, Empire State Plaza, Albany, NY 12201
A recent report in the New England Journal of Medicine on prenatal screening for Down’s syndrome 
(Malone et al 2005) received much attention in the non-scientiﬁ  c press, such as Time (Wallis 2005) and 
Forbes (Gordon 2005) magazines. This paper describes the results from a multicenter study that showed 
that, when an integrated, multi-marker approach was combined with a speciﬁ  c algorithm, it was pos-
sible to detect 90-95% of fetuses affected with trisomy 21 relatively early in a pregnancy with high 
accuracy, giving the prospective parents time to make appropriate choices. This study represents the 
culmination of over 25 years of research that has gradually increased the utility of prenatal screening 
for chromosomal defects. This effort started in the 1970s with the observation that there was an increased 
risk for chromosomal abnormalities, primarily trisomy 21, in mothers of advanced age at the time of 
pregnancy (Hook 1976a, b). In the mid 1980s it was shown that combining age with the results from 
AFP (alpha-fetoprotein) and beta-hCG (human chorionic gonadotropin) measurements in the maternal 
serum could increase the detection rate from below 40% to around 50-55% (Bogart et al 1987; Cuckle 
et al 1987). By 1990, the so-called triple test was developed, which takes into account the maternal age 
in combination with the levels of AFP, beta-hCG, and uE3 (unconjugated estriol) in the maternal serum 
during the second trimester of pregnancy, thereby achieving a detection rate of up to 70% for trisomy 
21 (Cuckle et al 1988; Wald et al 1989). This detection rate was further improved a few years later with 
the addition of dimeric inhibin A measurement to form the quadruple test, which increased the detection 
rate to almost 80% (Wald et al 1994a; Aitken et al 1996). Today, either the triple or quadruple test is 
the standard of prenatal care for expectant mothers and their unborn child. At the same time that the 
quadruple test was introduced, various groups started to develop tests that could be used earlier in a 
pregnancy, i.e, during the ﬁ  rst trimester, which led to the combination of the levels for the biochemical 
serum markers PAPP-A (pregnancy-associated plasma protein A) and free beta-hCG with the physical 
marker of nuchal translucency determined by ultrasound (Wald et al 1994b; Wald et al 1995; Wald and 
Hackshaw 1997). These developments ﬁ  nally culminated in two landmark studies, one in England 
(SURUSS) (Wald et al 2003), the other in the USA (FASTER) (Dugoff et al 2004; Malone et al 2005), 
that demonstrated that a combination or integration of second trimester screening with ﬁ  rst trimester 
screening gives the highest sensitivity for the prenatal detection of chromosomal defects, while at the 
same time keeping the false-positive rate low.
So, is there a lesson in this story for the early detection of cancer by screening? We believe so. It 
clearly shows that a combination of multiple markers, each of which by itself has limited sensitivity 
and/or speciﬁ  city, can lead to a powerful screening test. In cancer screening, the traditional approach 
has been to seek the one and only “silver bullet” type biomarker that detects all cancers early without 
too many false positive results. The latter characteristic is especially important because of the relatively 
low incidence of individual cancers among the general population, and the potentially multiple invasive, 
complex and expensive follow-up tests triggered by a positive screening result. Unfortunately, this 
magic marker has proven elusive, the occasional claim to the contrary notwithstanding. In contrast, the 
scientiﬁ  c literature is full of reports on initially promising new bio-markers that, when further inves-
tigated, turn out not to be that good after all. But are they really not good, or is it just a matter of the 
paradigm that they are expected to ﬁ  t? Perhaps, if a similar strategy to that successfully used in prena-
tal screening were adopted, some of these markers could be useful after all (Li et al 2005). Why not 
develop a multi-marker screening approach for cancer? Indeed, some form of multi-marker testing is 
al-ready in usage, and more are in development. For example, in the USA screening for prostate 
cancer in men over 50 years of age now consists of a digital rectal exam (DRE; a physical marker) and Schneider et al
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a PSA (prostate-speciﬁ  c antigen) test in serum 
(a biochemical marker), that together have a sub-
stantially higher detection rate than does either 
marker alone (Catalona et al 1994; Schröder 
et al 1998; Schröder et al 2001; Vis et al 2001). 
Furthermore, in cases where the results put the 
patient into the elevated risk, yet diagnostically 
ambiguous grey area – a PSA value between 4 and 
10 ng/ml and a negative DRE -a second biochem-
ical marker, namely free PSA, can be added, that 
helps to distinguish benign from malignant condi-
tions (Catalona et al 1995; Raaijmakers et al 2004). 
While far from perfect, and while certainly not yet 
as sophisticated as the integrated screening for 
fetal defects, this triple-marker approach for pros-
tate cancer has proven capable of detecting a 
substantial number of early cancers, although the 
effect of early detection on overall mortality from 
prostate cancer is still unclear (Postma and 
Schröder 2005). Other multi-marker test protocols, 
the ProstAsure index (Babaian et al 1998) and 
ProstataClass (Stephan et al 2002a, b), use neural 
network-derived, non-linear algorithms to calcu-
late the risk for prostate cancer from values for 
three serum markers and the patient’s age (Pros-
tAsure), or free and total PSA, DRE, patient age 
and prostate volume (ProstataClass). The latter 
algorithm introduces another physical marker, 
prostate volume, that is derived by an imaging 
technique, namely transrectal ultrasound or 
TRUS (http://www.charite.de/ch/uro/de/html/
prostatabiopsie/prostata_en.html, accessed 
2/13/2006). In direct comparisons these indices 
were shown to perform better than percent free 
PSA alone, and to signiﬁ  cantly reduce the number 
of unnecessary biopsies. However, it is not yet 
clear whether those early encouraging results will 
hold up in larger, prospective studies. Several other 
combinations of markers and algorithms have been 
proposed (Kamoi and Babaian 1999; Bauer and 
Moul 2000); it will be interesting to see which, if 
any, of these will survive more rigorous clinical 
studies and whether they ultimately will have an 
impact on prostate cancer mortality.
Another cancer for which a multi-marker 
approach has been attempted is ovarian cancer, for 
which currently no single good early detection 
marker exists. The most widely used biochemical 
marker for ovarian cancer is CA125 (Bast et al 
1998). However, while most advanced-stage 
cancers show elevated CA125 serum levels, the 
marker’s sensitivity for early-stage disease is less 
than 50% (Skates et al 2004). In order to improve 
early detection sensitivity without sacrificing 
speciﬁ  city, one or more additional markers, includ-
ing, among others, CA72-4, CA15-3, OVX1, lipid-
associated sialic acid (LASA,) and macrophage 
colony-stimulating factor (M-CSF), were added 
(Terry et al 2004; Bast et al 2005). The various 
combinations of markers were then evaluated with 
a number of prediction models and methods, 
including artiﬁ  cial neural networks, logistic regres-
sion, classiﬁ  cation trees and mixture discriminant 
analysis (Berek and Bast 1995; Woolas et al 1995; 
Zhang et al 2000; Skates et al 2004). As for prostate 
cancer detection, there was a clear perfor-
mance improvement when using multi-marker 
analyses, compared to measurement of CA125 
alone. Furthermore, a combination of new bio-
markers identiﬁ  ed through proteomics strategies 
also exhibited increased sensitivity and speciﬁ  city 
for the early detection of ovarian cancer (Zhang 
et al 2004). Finally, a novel recursive approach has 
shown that, instead of measuring multiple indi-
vidual analytes, it is feasible to analyze many 
markers simultaneously, using mass spectroscopy 
to determine patterns of markers, whereby the pat-
tern itself becomes the analytical entity. Thus, the 
pattern is what is diagnostic for the presence or 
absence of cancer (Petricoin et al 2002). Although 
the initial study has generated considerable con-
troversy, intensive efforts are now underway to 
further develop and validate this strategy.
Together, these examples clearly show that 
multi-marker screening can have its place in early 
cancer detection. So what, if anything, is holding 
us back? A priori, there seem to exist no scientiﬁ  c 
reasons why such an approach should not work for 
cancer screening. However, a number of issues 
need to be addressed before any multi-marker test 
can become the standard of care. As for any new 
clinical procedure, such a test has to be validated 
in large, well designed prospective trials.
One of the difﬁ  culties is that cancer is a rather 
complex disease, and therefore the conﬁ  rmation 
of whether cancer is indeed present or not after a 
positive screening result is rarely as easy and 
unequivocal as a karyotype for trisomy 21. 
Furthermore, whether the cancer will develop and 
cause clinical symptoms may not be known for 
many years, whereas after fetal defect marker 
testing the ultimate outcome will be known within Trisomy-21 and multi-marker cancer testing
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several months of the analysis. In addition, cancer 
screening is not just a one-time procedure, in 
contrast to screening for fetal defects, which has 
to be conducted only once during a pregnancy. 
Rather, screening for cancer needs to be periodi-
cally repeated during a person’s life, thereby rais-
ing a number of other issues. These include 
cost/beneﬁ  t and the appropriate interval between 
tests repetitions.
Finally, what is unique about the triple and 
quadruple test for prenatal fetal defect screening 
is that neither uses complex models; from an infor-
matics standpoint, their implementation amounts 
to simply counting positively ruling-in markers. 
Much of the modeling that is done today in the 
discovery phase of cancer biomarker studies 
explores highly computationally intensive multi-
variate prediction models (logistic regression, 
CART, PCA, support vector machines, neural 
networks) using dozens to hundreds, if not thou-
sands of individual markers. We wonder if, and 
how, these types of prediction models will general-
ize for use in the clinic, for several reasons. First, 
there is the technical challenge to accurately and 
reproducibly measure a large number of markers. 
Second, the current models seek and use all mark-
ers in a panel in all patients in a ﬁ  xed manner. 
Third, the output, while resulting in a speciﬁ  c class 
prediction, can be difﬁ  cult for clinicians to inter-
pret. This is in contrast to the triple/quadruple test, 
in which markers that ‘miss’ a positive clinical 
diagnosis for Trisomy-21 are provided ‘back-up’ 
by other markers that provide evidence for a 
positive diagnosis. Finally, the relative perfor-
mance of models generated using the various 
alternatives have not been sufﬁ  ciently explored.
While we think that complex fixed-marker 
models should continue to be explored, simpler 
models may be possible and ultimately needed to 
avoid some of the real and/or perceived limitations 
that lead to resistance in the adoption of the com-
plex models. Researchers involved in cancer 
biomarker model development should become 
aware of and consider simple current clinical 
diagnostics solutions, such as the triple/quadruple 
test, as a guide for their own diagnostic model 
formulation.
These and other key issues obviously need to be 
addressed before any new test will have a signiﬁ  cant 
impact on early cancer detection. Unless new and 
better individual cancer-specific markers are 
discovered, a multi-marker testing approach may 
hold the greatest promise for the improved early 
detection of cancer.
Acknowledgements
We would like to thank Dr. James Lyons-Weiler 
for suggesting this contribution, and for engaging 
in a discussion on simple vs. complex disease 
prediction model paradigms for cancer biomarker 
development.
References
Aitken DA, Wallace EM, Crossley JA, et al. (1996). “Dimeric inhibin A as 
a marker for Down’s syndrome in early pregnancy.” N Engl J Med 
334 (19): 1231-6.
Babaian RJ, Fritsche HA, Zhang Z, et al. (1998). “Evaluation of prostAsure 
index in the detection of prostate cancer: a preliminary report.” 
Urology 51(1): 132-6.
Bast RC, Jr., Badgwell D, Lu Z, et al. (2005). “New tumor markers: CA125 
and beyond.” Int J Gynecol Cancer 15 Suppl 3: 274-81.
Bast RC, Jr., Xu FJ, Yu YH, et al. (1998). “CA 125: the past and the future.” 
Int J Biol Markers 13(4): 179-87.
Bauer JJ and Moul JW (2000). Assessment of risk of prostate cancer: 
algorithms for diagnosis, staging, and prognosis. Advanced therapy 
of prostate disease. M. I. Resnick and I. M. Thompson. Lewiston, 
NY, B.C. Decker: 34-43.
Berek JS and Bast RC, Jr. (1995). “Ovarian cancer screening. The use of 
serial complementary tumor markers to improve sensitivity and 
speciﬁ  city for early detection.” Cancer 76(10 Suppl): 2092-6.
Bogart MH, Pandian MR and Jones OW (1987). “Abnormal maternal serum 
chorionic gonadotropin levels in pregnancies with fetal chromosome 
abnormalities.” Prenat Diagn 7(9): 623-30.
Catalona WJ, Richie JP, Ahmann FR, et al. (1994). “Comparision of digital 
rectal examination and serum prostate speciﬁ  c antigen in the early 
detection of prostate cancer: results of a multicenter clinical trial of 
6,630 men.” J. Urol. 151: 1283-1290.
Catalona WJ, Smith DS, Wolfert RL, et al. (1995). “Evaluation of percent-
age of free serum prostate-speciﬁ  c antigen to improve speciﬁ  city of 
prostate cancer screening.” JAMA 274: 1214-1220.
Cuckle HS, Wald NJ, Barkai G, et al. (1988). “First-trimester biochemical 
screening for Down syndrome.” Lancet 2(8615): 851-2.
Cuckle HS, Wald NJ and Thompson SG (1987). “Estimating a woman’s risk of 
having a pregnancy associated with Down’s syndrome using her age and 
serum alpha-fetoprotein level.” Br J Obstet Gynaecol 94(5): 387-402.
Dugoff L, Hobbins JC, Malone FD, et al. (2004). “First-trimester maternal 
serum PAPP-A and free-beta subunit human chorionic gonadotropin 
concentrations and nuchal translucency are associated with obstetric 
complications: a population-based screening study (the FASTER 
Trial).” Am J Obstet Gynecol 191(4): 1446-51.
Gordon S. (2005). “Test Detects Down Syndrome Early.” Forbes Retrieved 
Dec. 15, 2005, from http://www.forbes.com/lifestyle/health/feeds/ 
hscout/2005/11/09/hscout529032.html.
Hook EB (1976a). “Estimates of maternal age-speciﬁ  c risks of Down-
syndrome birth in women aged 34-41.” Lancet 2(7975): 33-4.
Hook EB (1976b). “Risk of Down syndrome in relation to maternal age.” 
Lancet 2(7983): 465.
Kamoi K and Babaian RJ (1999). “Advances in the application of prostate-
speciﬁ  c antigen in the detection of early-stage prostate cancer.” Semin 
Oncol 26(2): 140-9.Schneider et al
47 Cancer Informatics 2006:2 
Li J, Orlandi R, White CN, et al. (2005). “Independent validation of 
candidate breast cancer serum biomarkers identiﬁ  ed by mass spec-
trometry.” Clin Chem 51(12): 2229-35.
Malone FD, Canick JA, Ball RH, et al. (2005). “First-trimester or second-
trimester screening, or both, for Down’s syndrome.” N Engl J Med 
353(19): 2001-11.
Petricoin EF, Ardekani AM, Hitt BA, et al. (2002). “Use of proteomic 
patterns in serum to identify ovarian cancer.” Lancet 359(9306): 
572-7.
Postma R and Schröder FH (2005). “Screening for prostate cancer.” Eur J 
Cancer 41(6): 825-33.
Raaijmakers R, Blijenberg BG, Finlay JA, et al. (2004). “Prostate cancer 
detection in the prostate speciﬁ  c antigen range of 2.0 to 3.9 ng/ml: 
value of percent free prostate speciﬁ  c antigen on tumor detection and 
tumor aggressiveness.” J Urol 171(6 Pt 1): 2245-9.
Schröder FH, Roobol-Bouts M, Vis AN, et al. (2001). “Prostate-speciﬁ  c 
antigen-based early detection of prostate cancer—-validation of 
screening without rectal examination.” Urology 57(1): 83-90.
Schröder FH, van der Maas P, Beemsterboer P, et al. (1998). “Evaluation 
of the digital rectal examination as a screening test for prostate cancer. 
Rotterdam section of the European Randomized Study of Screening 
for Prostate Cancer.” J Natl Cancer Inst 90(23): 1817-23.
Skates SJ, Horick N, Yu Y, et al. (2004). “Preoperative sensitivity and 
speciﬁ  city for early-stage ovarian cancer when combining cancer 
antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-
stimulating factor using mixtures of multivariate normal distribu-
tions.” J Clin Oncol 22 (20): 4059-66.
Stephan C, Cammann H, Semjonow A, et al. (2002a). “Multicenter Evalu-
ation of an Artiﬁ  cial Neural Network to Increase the Prostate Cancer 
Detection Rate and Reduce Unnecessary Biopsies.” Clin Chem  48(8): 
1279-1287.
Stephan C, Jung K, Cammann H, et al. (2002b). “An artiﬁ  cial neural network 
considerably improves the diagnostic power of percent free prostate-
speciﬁ  c antigen in prostate cancer diagnosis: results of a 5-year 
investigation.” Int J Cancer 99(3): 466-73.
Terry KL, Sluss PM, Skates SJ, et al. (2004). “Blood and urine markers 
for ovarian cancer: a comprehensive review.” Dis Markers 20(2): 
53-70.
Vis AN, Hoedemaeker RF, Roobol M, et al. (2001). “Tumor characteristics 
in screening for prostate cancer with and without rectal examination 
as an initial screening test at low PSA (0.0-3.9 ng/ml).” Prostate 
47(4): 252-61.
Wald NJ, Cuckle HS, Sneddon J, et al. (1989). “Screening for Down 
syndrome.” Am J Hum Genet 44(4): 586-90.
Wald NJ, Densem JW, Smith D, et al. (1994a). “Four-marker serum 
screening for Down’s syndrome.” Prenat Diagn 14(8): 707-16.
Wald NJ and Hackshaw AK (1997). “Combining ultrasound and biochemistry 
in ﬁ  rst-trimester screening for Down’s syndrome.” Prenat Diagn 
17(9): 821-9.
Wald NJ, Kennard A and Hackshaw AK (1995). “First trimester serum 
screening for Down’s syndrome.” Prenat Diagn 15(13): 1227-40.
Wald NJ, Kennard A and Smith D (1994b). “First trimester biochemical 
screening for Down’s syndrome.” Ann Med 26(1): 23-9.
Wald NJ, Rodeck C, Hackshaw AK, et al. (2003). “First and second trimes-
ter antenatal screening for Down’s syndrome: the results of the Serum, 
Urine and Ultrasound Screening Study (SURUSS).” Health Technol 
Assess 7(11): 1-77.
Wallis C. (2005). “The Down Dilemma.” Time Retrieved Dec. 15, 2005, 
from http://www.time.com/time/archive/preview/0, 10987,
1129545,00.html.
Woolas RP, Conaway MR, Xu F, et al. (1995). “Combinations of multiple 
serum markers are superior to individual assays for discriminat-
ing malignant from benign pelvic masses.” Gynecol Oncol 59(1): 
111-6.
Zhang Z, Bast RC, Jr., Yu Y, et al. (2004). “Three biomarkers identiﬁ  ed 
from serum proteomic analysis for the detection of early stage ovar-
ian cancer.” Cancer Res 64(16): 5882-90.
Zhang Z, Zhang H and Bast RC (2000). An application of artiﬁ  cial neural 
networks in ovarian cancer early detection. IEEE-INNS-ENNS 
Internationa Joint Conference on Neural Networks (IJCNN’00).